An inner pore residue (Asn406) in the NaV1.5 channel controls slow inactivation and enhances mibefradil block to T-type Ca2+ channel levels

Molecular Pharmacology

Volumn 70, Issue 5, 2006, Pages 1514-1523

  McNulty, Megan M ^a   Kyle, John W ^a   Lipkind, Gregory M ^a   Hanck, Dorothy A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MC6094 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; CALCIUM CHANNEL T TYPE; CYSTEINE; LOCAL ANESTHETIC AGENT; MIBEFRADIL; PHENYLALANINE; VOLTAGE GATED SODIUM CHANNEL;

AMINO ACID SUBSTITUTION; ARTICLE; DRUG ACTIVITY; DRUG BINDING SITE; DRUG SENSITIVITY; HYDROPHOBICITY; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN;

AMINO ACID SEQUENCE; ASPARAGINE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; HUMANS; ION CHANNEL GATING; KINETICS; MIBEFRADIL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUSCLE PROTEINS; MUTATION; SODIUM CHANNELS;

EID: 33751193498     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.027177     Document Type: Article

References (25)

1. 2+ channels. Annu Rev Cell Dev Biol 16:521-555.
2. Catterall WA (2002) Molecular mechanisms of gating and drug block of sodium channels. Novartis Found Symp 241:206-218; discussion 218-232.
3. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 54:695-703.
4. Eller P, Berjukov S, Wanner S, Huber I, Hering S, Knaus HG, Toth G, Kimball SD, and Striessnig J (2000) High affinity interaction of mibefradil with voltage-gated calcium and sodium channels. Br J Pharmacol 130:669-677.
5. Fozzard HA and Hanck DA (1996) Structure and function of voltage-dependent sodium channels: comparison of brain II and cardiac isoforms. Physiol Rev 76:887-926.
6. 2+ current. Am J Physiol 280:C1327-C1339.
7. + channel inactivation gating. Circ Res 75:114-122.
8. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, and MacKinnon R (2002) Crystal structure and mechanism of a calcium-gated potassium channel. Nature (Lond) 417:515-522.
9. + channels. Mol Pharmacol 64:741-752.
10. Lipkind GM and Fozzard HA (2005) Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol 68:1611-1622.
11. Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, and Hanck DA (2000) Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther 295:302-308.
12. + channels. Mol Pharmacol 66:1652-1661.
13. Nau C, Wang SY, Strichartz GR, and Wang GK (1999) Point mutations at N434 in D1-S6 of μ1 Na(+) channels modulate binding affinity and stereoselectivity of local anesthetic enantiomers. Mol Pharmacol 56:404-413.
14. - channels in macrovascular endothelial cells. Br J Pharmacol 121:547-555.
15. + channel. Biochem Biophys Res Commun.
16. + channel chimaeras. J Physiol 515:61-73.
17. Perchenet L and Clement-Chomienne O (2000) Characterization of mibefradil block of the human heart delayed rectifier hKv1.5. J Pharmacol Exp Ther 295:771-778.
18. Richmond JE, Featherstone DE, Hartmann HA, and Ruben PC (1998) Slow inactivation in human cardiac sodium channels. Biophys J 74:2945-2952.
19. 2+ channel in cardiac tissue. Eur J Pharmacol 280:155-158.
20. Satin J, Kyle JW, Chen M, Bell P, Cribbs LL, Fozzard HA, and Rogart RB (1992) A mutant of TTX-resistant cardiac sodium channels with TTX-sensitive properties. Science (Wash DC) 256:1202-1205.
21. + channels. J Gen Physiol 110:23-33.
22. + channels. Mol Pharmacol 54:389-396.
23. Wang SY and Wang GK (1997) A mutation in segment I-S6 alters slow inactivation of sodium channels. Biophys J 72:1633-1640.
24. + channels resistant to batrachotoxin. Proc Natl Acad Sci USA 95:2653-2658.
25. + channel alpha subunit in voltage-dependent gating and drug block. J Biol Chem 277:35393-35401.